. 2017 Feb 2;18:52. doi: 10.1186/s13063-017-1777-y

Table 2.

Eligibility criteria

Inclusion	Exclusion
≥18 years Diagnosis of moderate to severe plaque psoriasis (PASI ≥8) Adalimumab naïve Candidate for biologic therapy Willing and able to use adequate contraceptives during the study	History of significant MTX toxicity, intolerability, or contraindication Known liver or kidney malfunction Alcohol abuse Bone marrow hypoplasia, leukocytopenia, thrombocytopenia, or significant anemia Known severe or chronic infections like tuberculosis or HIV Ulcers in the oral cavity or known active ulcers in digestive tract Pregnant or nursing women Need for live vaccinations Use of other immunosuppressive medication (e.g., prednisone, mycophenolate mofetil (Cellcept), cyclosporine (Neoral), sirolimus (Rapamune), systemic tacrolimus (Prograf))

Inclusion

Exclusion

≥18 years
Diagnosis of moderate to severe plaque psoriasis (PASI ≥8)
Adalimumab naïve
Candidate for biologic therapy
Willing and able to use adequate contraceptives during the study

History of significant MTX toxicity, intolerability, or contraindication Known liver or kidney malfunction
Alcohol abuse
Bone marrow hypoplasia, leukocytopenia, thrombocytopenia, or significant anemia
Known severe or chronic infections like tuberculosis or HIV
Ulcers in the oral cavity or known active ulcers in digestive tract
Pregnant or nursing women
Need for live vaccinations
Use of other immunosuppressive medication (e.g., prednisone, mycophenolate mofetil (Cellcept), cyclosporine (Neoral), sirolimus (Rapamune), systemic tacrolimus (Prograf))